Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Sleepman who wrote (26480)	11/13/1998 8:50:00 PM
From: Pseudo Biologist	Read Replies (3) \| Respond to of 32384

Dan, before getting too excited about this, one should realize the Novartis/Simulect royalty is under 1% of net sales. ("The Company" below refers to Seragen. This is a document dealing with the acquisition.) <<NOVARTIS In March 1996, the Company entered into a license agreement with Novartis, formerly Sandoz Pharmaceutical, Limited, whereby the Company granted Novartis a non-exclusive sub-license of certain patents in exchange for a $1.5 million non-refundable payment. Under the terms of the license agreement, beginning on January 1, 2001 Novartis will be required to pay a 0.75% royalty on the net sales price of licensed products that are sold under the sub-license agreement. The agreement is to remain in effect until expiration of the Company's licensed patents, or earlier upon termination as defined.>> From: LIGAND PHARMACEUTICALS INC S-4 (07/09/1998) sec.gov